title: The HEART study:  a real-world experience using the CID Chrono Carbostent in primary and rescue PCI.
abstract: BACKGROUND
  Chrono Carbostent (CID, Saluggia, Italy) is characterized by a peculiar coating with Carbofilm which could reduce the risk of thrombosis as compared to other bare metal stents (BMS). This feature should be particularly useful in the setting of primary or rescue percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI).
  
  
  METHODS
  We tested the efficacy and safety of this stent in patients with STEMI undergoing primary or rescue PCI. Inclusion criteria included the diagnosis of STEMI, a coronary anatomy suitable for stenting and no contraindications to dual antiplatelet therapy for at least 1 month. The primary endpoint was the composite of the following major adverse cardiac events (MACEs) at 12 months: death, recurrence of myocardial infarction and target vessel revascularization.
  
  
  RESULTS
  One hundred and seven STEMI patients treated with Chrono Carbostent implantation were enrolled. Eighty-three (77%) patients underwent primary and 24 (23%) rescue PCI. A total of 148 stents were successfully implanted. Cardiogenic shock was present in 12 (11%) patients and in-hospital mortality was 6.5%. Cumulatively, the rate of MACEs at 12 months was 17.7% (deaths 7.4%, target lesion revascularization 9.3%).
  
  
  CONCLUSIONS
  In unselected patients with STEMI treated by urgent PCI, the Chrono Carbostent showed a low rate of events in those patients surviving the acute phase of myocardial infarction. Unfortunately, and especially for patients in cardiogenic shock, survival continued to be relatively independent of interventional treatment, even when successfully completed, thus strictly linking prognosis of STEMI to severity of clinical presentation.
authors: Institute of Cardiology, Catholic University of the Sacred Heart, Rome, Italy. antoniomarialeone@yahoo.it
authors: Antonio Maria
authors: AM
authors: Leone
authors: Gregory Angelo
authors: GA
authors: Sgueglia
authors: Italo
authors: I
authors: Porto
authors: Giampaolo
authors: G
authors: Niccoli
authors: Francesco
authors: F
authors: Burzotta
authors: Carlo
authors: C
authors: Trani
authors: Alberto Ranieri
authors: AR
authors: De Caterina
authors: Antonino
authors: A
authors: Buffon
authors: Mario Attilio
authors: MA
authors: Mazzari
authors: Rocco
authors: R
authors: Mongiardo
authors: Antonio Giuseppe
authors: AG
authors: Rebuzzi
authors: Filippo
authors: F
authors: Crea
mesh_terms: D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D016009:Chi-Square Distribution; D002858:Chromium Alloys; D000077144:Clopidogrel; D020099:Coated Materials, Biocompatible; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D005260:Female; D017052:Hospital Mortality; D061847:Hospitals, High-Volume; D006801:Humans; D007558:Italy; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009203:Myocardial Infarction / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D016017:Odds Ratio; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects / Q000295:instrumentation* / Q000401:mortality; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016016:Proportional Hazards Models; D011474:Prosthesis Design; D012008:Recurrence; D012042:Registries; D012307:Risk Factors; D012720:Severity of Illness Index; D012770:Shock, Cardiogenic / Q000209:etiology / Q000401:mortality; D015607:Stents; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D002858:Chromium Alloys; D020099:Coated Materials, Biocompatible; D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin